Cargando…
Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
BACKGROUND: Psoriasis is a debilitating autoimmune skin disease that affects 2%–3% of the world’s population. Patients with moderate-to-severe plaque psoriasis suffer from a decreased quality of life as well as comorbidities. Newer biological agents have been shown to be more effective than traditio...
Autores principales: | Ren, Vicky, Dao, Harry |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3600940/ https://www.ncbi.nlm.nih.gov/pubmed/23515267 http://dx.doi.org/10.2147/CCID.S42424 |
Ejemplares similares
-
Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
por: Sekhon, Sahil, et al.
Publicado: (2017) -
Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy
por: Giunta, Alessandro, et al.
Publicado: (2017) -
Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab
por: Hanley, Tessa L, et al.
Publicado: (2017) -
Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain
por: Johansson, Erin, et al.
Publicado: (2018) -
Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes
por: Egeberg, Alexander, et al.
Publicado: (2023)